2018 American Transplant Congress
Treatment Outcomes of FSGS Recurrence
Background: Recurrence of FSGS (focal segmental glomerulosclerosis) after kidney transplant occurs in 30% of adults and up to 80% of children and has impact on…2018 American Transplant Congress
Modified Protocol for ABO-Incompatible Living Donor Liver Transplantation with Rituximab and Intravenous Immunoglobulin without Plasma Exchange
Center for Liver Cancer, National Cancer Center, Il-san Donggu, Goyang, Republic of Korea.
Purpose: Since a variety of desensitization strategies including rituximab, intravenous immunoglobulin (IVIG), and plasma exchange (PE) have been introduced, the survival and outcomes of recipients…2018 American Transplant Congress
modified DFPP Can Eliminate Donor-Reactive IgG Antibody with Preserving Fibrinogen before Kidney Transplantation
BACKGROUND: Elimination of preexisting IgG antibodies against donor antigen is an important role before antibody-incompatible (i.e. ABO-incompatible and donor-specific antibody positive) kidney transplantation. Plasma exchange…2018 American Transplant Congress
How Safe is Crossing the ABO Blood Group Barrier? A Meta-Analysis to Determine the Additive Risk of ABO-Incompatible Kidney Transplantation
Nephrology and Kidney Transplantation, Erasmus Medical Center, Rotterdam, Netherlands.
Background ABO blood group-incompatible (ABOi) kidney transplantation is considered a safe procedure, with non-inferior outcomes in large cohort studies. Its contribution to living kidney transplantation…2018 American Transplant Congress
The Inhibitory Effect of Plasma on Activation of Lymphocytes from Kidney Transplants is Significantly More Severe in Tacrolimus Based Regimen: What Implications for Plasma Exchange Role in Anti-Rejection Therapy?
Background:Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented. However, trial…2018 American Transplant Congress
Contemporary Desensitization with Low Dose Rituximab Ensures Kidney Transplant Outcome beyond ABO Blood Type Incompatibility:A Comparison between past Regimens in Single Institute
Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan.
INTRODUCTION: An ABO incompatible kidney transplant (ABOiKT) requires desensitization (DS). The ways of DS have been changed chronologically and the outcome could have been subsequently…2018 American Transplant Congress
Long-Term Success of Treatment for Cardiac Transplant AMR May Depend Upon Suppressing Class II Donor Specific Antibodies
Antibody mediated rejection (AMR) in cardiac transplant (tspt) patients (pts) is primarily mediated by donor specific antibodies (DSAs) and associated with reduced long-term graft survival.…2017 American Transplant Congress
Prognostic Tools to Choose Candidates for Successful Desensitization.
1Northwestern University, Chicago, IL; 2Johns Hopkins, Baltimore, MD
Antibodies to donor HLA antigens are a barrier to solid organ transplantation. Strategies to desensitize patients have improved, but the ability to predict response to…2017 American Transplant Congress
Successful Launch of an ABO-Incompatible Kidney Transplantation Program to Overcome the Shortage of Compatible Living Donors: Experience at a Single Center.
Introduction:ABO-incompatible (ABOi) kidney transplantation (KT) is being increasingly performed to overcome donor shortages. However, debate persists regarding the post-transplant outcomes of ABOi KT versus that…2017 American Transplant Congress
Outcome of ABO-Incompatible Kidney Transplantation After Stratified Desensitization.
Background. Plasmapheresis for antibody removal and rituximab for antibody production suppression are performed for desensitization against ABO-incompatible kidney transplantation. We evaluated clinical outcome for optimizing…
American Transplant Congress abstracts